CD274 and neoplasm: In order to identify appropriate candidates for immunotherapy and tailor immunotherapy treatment strategies, some biomarkers are being developed based on tumor PD-L1 expression, tumor mutational burden (TMB), tumor-infiltrating lymphocytes (TILs), and several other factors [8].